Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

63.88 +0.49 (+0.77%)
Streaming Delayed Price Updated: 12:52 PM EST, Nov 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,090,347
Open 63.65
Bid (Size) 63.87 (7)
Ask (Size) 63.88 (1)
Prev. Close 63.39
Today's Range 63.31 - 64.13
52wk Range 60.47 - 87.67
Shares Outstanding N/A
Dividend Yield 1.46%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Not-So-Big Pharma
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
Exposures Product Safety

Performance

YTD
-6.61%
-6.61%
1 Month
-17.51%
-17.51%
3 Month
-24.65%
-24.65%
6 Month
-17.16%
-17.16%
1 Year
+0.14%
+0.14%

More News

Read More
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It
Via Benzinga
WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill
Via Benzinga
Topics Government
Exposures Political
Earnings Scheduled For November 12, 2024
Via Benzinga
A Closer Look at AstraZeneca's Options Market Dynamics
Via Benzinga
Smart Money Is Betting Big In AZN Options
Via Benzinga
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower
Via Benzinga
Topics Government
Exposures Political
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?
Via The Motley Fool
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
Via Benzinga
AstraZeneca Plc (AZN) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'
Via Benzinga
AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter Beat
Via Investor's Business Daily
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
From AstraZeneca
Via Business Wire
AstraZeneca’s 9M and Q3 2024 results
From AstraZeneca
Via Business Wire
The Week Kamala Harris Lost (Nov 4-8), These Large Cap Stocks Lost Big
Via Benzinga
AstraZeneca Q3 Earnings Preview: Will Cancer, Heart Drugs Fuel Continued Growth?
Via Benzinga
AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis
Via Benzinga
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
From AstraZeneca
Via Business Wire
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024
From AstraZeneca
Via Business Wire
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Via Benzinga
Why Is AstraZeneca Stock Sinking On Tuesday?
Via Benzinga
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
Via Talk Markets
AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug
Via Benzinga
3 Magnificent Stocks Under $100 to Buy in November
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.